将药物基因组学临床决策支持系统应用于德国医院。
Implementing Pharmacogenomic Clinical Decision Support into German Hospitals.
作者信息
Hinderer Marc, Boerries Melanie, Boeker Martin, Neumaier Michael, Loubal Frank-Peter, Acker Till, Brunner Manfred, Prokosch Hans-Ulrich, Christoph Jan
机构信息
Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
Albert-Ludwigs-University Freiburg, Germany.
出版信息
Stud Health Technol Inform. 2018;247:870-874.
BACKGROUND
Pharmacogenomic Clinical Decision Support Systems (CDSS) are considered to be the most feasible tool for adopting pharmacogenomic testing into clinical routine.
OBJECTIVE
To discuss important factors for implementing pharmacogenomic CDSS into German hospitals.
METHODS
We analyzed two relevant studies. Furthermore, we interviewed data privacy officers of three German university hospitals and examined relevant legal regulations in literature.
RESULTS
There are three major barriers for implementing pharmacogenomic CDSS into German hospitals: (i) the legal uncertainty; (ii) the lack of machine-readable data; (iii) the remaining knowledge gap of both genetics and pharmacogenomics among physicians.
CONCLUSION
The implementation of passive clinical decision support (CDS) for somatic mutations in the form of structured pharmacogenomic reports might be the most feasible CDS feature for clinicians in German hospitals.
背景
药物基因组学临床决策支持系统（CDSS）被认为是将药物基因组学检测纳入临床常规的最可行工具。
目的
探讨在德国医院实施药物基因组学CDSS的重要因素。
方法
我们分析了两项相关研究。此外，我们采访了三家德国大学医院的数据隐私官员，并研究了文献中的相关法律法规。
结果
在德国医院实施药物基因组学CDSS存在三大障碍：（i）法律不确定性；（ii）缺乏机器可读数据；（iii）医生在遗传学和药物基因组学方面仍存在知识差距。
结论
以结构化药物基因组学报告的形式对体细胞突变实施被动临床决策支持（CDS）可能是德国医院临床医生最可行的CDS功能。
Zotero 插件